Patents by Inventor H. Michael Shepard

H. Michael Shepard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220372151
    Abstract: Provided are methods of treatment of cancers with combinations of and compositions containing a soluble hyaluronidase, such as a polymer-modified soluble hyaluronidase, and an immune checkpoint inhibitor for treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
    Type: Application
    Filed: June 27, 2022
    Publication date: November 24, 2022
    Inventors: Sanna ROSENGREN, H. Michael SHEPARD, Curtis B. THOMPSON
  • Publication number: 20220288226
    Abstract: Provided are molecular constructs that target tumor necrosis factor receptor 1 (TNFR1) and/or tumor necrosis factor receptor 2 (TNFR2). The constructs are for treating diseases, disorders, and conditions in which these receptors and/or TNF are involved in the etiology or in which their inhibition or activation thereof can ameliorate the disease, disorder, and condition or a symptom thereof. Among the constructs provided herein, are TNFR1 antagonist constructs that are engineered to inhibit TNFR1 function, and to eliminate any TNFR1 agonist activity. The constructs provided herein include agonists and antagonists of TNFR1 and TNFR2 Included also are agonists and antagonists of TNFR2. Agonists of TNFR2 increase regulatory T-cell function to control acute or chronic inflammation. Antagonists of TNFR2 decrease regulatory T-cell function thus increasing immunity, and are for treating cancer and certain immunodeficiency diseases.
    Type: Application
    Filed: April 28, 2022
    Publication date: September 15, 2022
    Inventor: H. Michael SHEPARD
  • Patent number: 11414489
    Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: August 16, 2022
    Assignee: Halozyme, Inc.
    Inventors: Sanna Rosengren, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20220175945
    Abstract: The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 9, 2022
    Inventor: H. Michael SHEPARD
  • Publication number: 20210284985
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 16, 2021
    Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Publication number: 20210277376
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Patent number: 11066656
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 20, 2021
    Assignee: Halozyme, Inc.
    Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Patent number: 11041149
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: June 22, 2021
    Assignee: Halozyme, Inc.
    Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Patent number: 10865400
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 15, 2020
    Assignee: Halozyme, Inc.
    Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Publication number: 20200318091
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 8, 2020
    Inventors: GE WEI, H. MICHAEL SHEPARD, QIPING ZHAO, ROBERT JAMES CONNOR
  • Publication number: 20200255814
    Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
    Type: Application
    Filed: March 19, 2020
    Publication date: August 13, 2020
    Inventors: Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
  • Publication number: 20190083449
    Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
    Type: Application
    Filed: October 18, 2018
    Publication date: March 21, 2019
    Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
  • Patent number: 10137104
    Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 27, 2018
    Assignee: Halozyme, Inc.
    Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20180216095
    Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
    Type: Application
    Filed: March 29, 2018
    Publication date: August 2, 2018
    Inventors: Christopher D. THANOS, Lin Wang, H. Michael Shepard
  • Patent number: 9969998
    Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 15, 2018
    Assignee: Halozyme, Inc.
    Inventors: Christopher D. Thanos, Lin Wang, H. Michael Shepard
  • Patent number: 9913822
    Abstract: Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 13, 2018
    Assignee: Halozyme, Inc.
    Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20180044419
    Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 15, 2018
    Inventors: Sanna ROSENGREN, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20170290796
    Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 12, 2017
    Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20170218069
    Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
    Type: Application
    Filed: February 27, 2017
    Publication date: August 3, 2017
    Inventors: Sanna ROSENGREN, H. Michael Shepard, Curtis B. Thompson
  • Publication number: 20170166878
    Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
    Type: Application
    Filed: April 8, 2016
    Publication date: June 15, 2017
    Inventors: Christopher D. Thanos, Lin Wang, H. Michael Shepard